34 patents
Page 2 of 2
Utility
Agonistic Antibodies That Bind Human CD40 and Uses Thereof
2 Dec 20
Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed.
Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
Filed: 17 Apr 17
Utility
Agonistic Antibodies That Bind Human CD40 and Uses Thereof
25 Nov 20
Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed.
Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
Filed: 5 Aug 20
Utility
Methods of treating by administering anti-kit antibodies
5 Oct 20
Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies.
Yaron Hadari, Elizabeth M. Mandel-Bausch, Susanne Radke, Joseph Schlessinger, Yoshihisa Suzuki
Filed: 9 Dec 18
Utility
Methods of treating by administering anti-kit antibodies
21 Sep 20
Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies.
Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
Filed: 13 Dec 18
Utility
Treatment of eosinophil or mast cell related disorders
14 Sep 20
Provided herein are methods and uses involving antibodies that specifically bind to a KIT receptor tyrosine kinase for managing, treating, or preventing an eosinophil or mast cell related disorder and/or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).
Theresa Marie LaVallee, Gerald McMahon
Filed: 6 Feb 19
Utility
Anti-ErbB antibodies and methods of use thereof
17 Aug 20
Provided herein are compositions, methods and uses involving antibodies that bind to ErbB, a receptor tyrosine kinase, and modulate the activity of ErbB.
Joseph Schlessinger, Diego Alvarado, Sangwon Lee
Filed: 9 Apr 15
Utility
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
1 Jun 20
This disclosure provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody.
Vladimir Coric, Tibor Keler, Thomas Davis
Filed: 2 Jun 17
Utility
Anti-ALK Antibodies and Methods for Use Thereof
20 May 20
Provided herein are compositions, methods and uses involving antibodies that specifically bind to ALK, a receptor tyrosine kinase, and modulate the expression and/or activity of ALK.
Diego ALVARADO, Jay LILLQUIST, Qwenda LIGON, Michael FELDHAUS
Filed: 25 Aug 16
Utility
Agonistic antibodies that bind CD40
27 Apr 20
Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed.
Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
Filed: 4 Apr 19
Utility
ANTI-CD27 and ANTI-PD-L1 Antibodies and Bispecific Constructs
8 Apr 20
Provided herein are novel anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain.
Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE
Filed: 16 Apr 19
Utility
Use of ANTI-PD-1 Antibody In Combination with ANTI-CD27 Antibody In Cancer Treatment
22 Jan 20
This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody.
Vladimir CORIC, Tibor KELER, Thomas DAVIS
Filed: 7 Jul 19
Utility
Vaccine Compositions
4 Dec 19
The present disclosure relates to vaccine compositions, particularly KLH-peptide conjugates, and methods of making such compositions.
Syed Saleem AHMED, John Joseph BUCKLEY, III, Lavinia Marina LEWIS, Brandi Rae OSBORNE, Sandipan SINHA, Jennifer Marie THORN, Ferhana ZAMAN
Filed: 9 Jan 19
Utility
Chimeric Antigen Receptors Targeting TIM-1
6 Nov 19
The invention provides chimeric antigen receptors (CARs) that specifically bind to the T-cell immunoglobulin and mucin domain 1 (TIM-1) protein.
Terrance A. STADHEIM, Joana M. MURAD, Jake REDER, Henry C. MARSH, JR., Li-Zhen HE, Tibor KELER
Filed: 11 Jan 18
Utility
Agonistic Antibodies That Bind Human CD40 and Uses Thereof
23 Oct 19
Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed.
Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
Filed: 4 Apr 19